Drug Trial Radar · NCT04158648
A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
73
Actual
Start
Feb 10, 2020
Primary completion
Oct 30, 2021
Study completion Dec 19, 2025
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, single-arm study designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of emicizumab in participants with mild or moderate hemophilia A without inhibitors against factor VIII (FVIII).
Conditions
- Mild Hereditary Factor VIII Deficiency Disease Without Inhibitor
- Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor
- Hemophilia A
Interventions
EmicizumabDrug
Four loading doses of emicizumab 3 milligrams per kilogram of body weight (mg/kg) will be administered subcutaneously (SC) once a week (QW) for 4 weeks followed by participant's preference of one of the three following maintenance SC dose regimens: 1.5 mg/kg QW, 3 mg/kg once every 2 weeks (Q2W), or 6 mg/kg once every 4 weeks (Q4W).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Model-Based Annualized Bleed Rate for Treated BleedsTime frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
- Mean Calculated ABR for Treated BleedsTime frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
- Median Calculated ABR for Treated BleedsTime frame: From the day of first emicizumab dose to at least 52 weeks of emicizumab treatment (median [range, min-max] efficacy period: 55.64 [8.6-89.9] weeks)
Locations
22 sites in 10 countries. Site status is shown where the registry gives one.
Childrens Hospital LA
Los Angeles, California
Hemophilia of Georgia Center for Bleeding & Clotting Disorders
Atlanta, Georgia
Indiana Hemophilia & Thrombosis center
Indianapolis, Indiana
University of Michigan, C.S. Mott Children's Hospital
Ann Arbor, Michigan
Washington Institute for Coagulation
Seattle, Washington
Cliniques Universitaires St-Luc
Brussels, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Kaye Edmonton Clinic
Edmonton, Alberta, Canada
Eastern Health - General Hospital
St. John's, Newfoundland and Labrador, Canada
Hopital Cardio-vasculaire Louis Pradel
Bron, France
CH de Bicetre
Le Kremlin-Bicêtre, France
Groupe Hospitalier Necker Enfants Malades
Paris, France
Universitätsklinikum Bonn
Bonn, Germany
Klinikum der Universität München, Campus Innenstadt
München, Germany
Amsterdam UMC Location AMC
Amsterdam, Netherlands
Instytut Hematologii i Transfuzjologii
Warsaw, Poland
Charlotte Maxeke Johannesburg Hospital
Johannesburg, South Africa
Hospital Universitario la Paz
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Cardiff and Vale NHS Trust
Cardiff, United Kingdom
Royal Free Hospital
London, United Kingdom
Great Ormond street Hospital for Children NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.